1. Why This Matters Now Rare disease drugs now account for 52% of all new molecular entities (NMEs) approved by […]

A Comprehensive Industry Report regarding the Technological, Economic, and Regulatory Transformation of the Pharmaceutical Sector (2025-2030) Executive Summary: The End

For IP counsel, portfolio managers, R&D leads, and institutional investors who need to move faster than the competition. Why Drug

1. The R&D Productivity Crisis: What the Numbers Actually Say The pharmaceutical industry’s core operating model has a compounding cost

Deconstructing the Middleman: Beyond the Textbook Definition To truly grasp the PBM’s role, we must look past the simple definition

1. The Scale of the Cliff: $236 Billion in Revenue at Risk Through 2030 The pharmaceutical industry is heading into

Generic drug companies fill more than 90% of all U.S. prescriptions and have saved the healthcare system an estimated $3.1

Section 1: The Regulatory Trinity: Anatomy of the Three Small-Molecule Pathways Why the Categorization Matters More Than Most Teams Think

1. What Pharmaceutical Portfolio Management Actually Is (and What Most Teams Get Wrong) Pharmaceutical portfolio management is the discipline of